| Revision as of 06:57, 31 August 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or [[user talk:CheM← Previous edit | Revision as of 15:28, 7 December 2011 edit undoJohn of Reading (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers767,601 editsm Typo fixing, replaced: to breakdown → to break down using AWBNext edit → | ||
| Line 58: | Line 58: | ||
| | melting_point = 114 | | melting_point = 114 | ||
| }} | }} | ||
| '''Miglitol''' is an oral ] that acts by inhibiting the ability of the patient to |
'''Miglitol''' is an oral ] that acts by inhibiting the ability of the patient to break down complex carbohydrates into glucose. It is primarily used in ] for establishing greater ] by preventing the digestion of ]s (such as ]s, ]s, and ]s) into ]s which can be absorbed by the body. | ||
| Miglitol inhibits ] enzymes called ]s. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of ] ]. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet. | Miglitol inhibits ] enzymes called ]s. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of ] ]. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet. | ||
Revision as of 15:28, 7 December 2011
 | This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Miglitol" – news · newspapers · books · scholar · JSTOR (October 2006) (Learn how and when to remove this message) |
 | |
| Clinical data | |
|---|---|
| Trade names | Glyset |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601079 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Dose-dependent |
| Protein binding | Negligible (<4.0%) |
| Metabolism | Nil |
| Elimination half-life | 2 hours |
| Excretion | Renal (95%) |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.069.670  |
| Chemical and physical data | |
| Formula | C8H17NO5 |
| Molar mass | 207.224 g/mol g·mol |
| 3D model (JSmol) | |
| Density | 1.458 g/cm |
| Melting point | 114 °C (237 °F) |
SMILES
| |
InChI
| |
| (verify) | |
Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to break down complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.
Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.
In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.
See also
 | This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it. |